- BySeeking Alpha-
On the 31st of March, Wasatch Advisors purchased 3.8 million StepStone Group Inc. (STEP) shares for $133 million at an average price of $35.27 per share. Shares of StepStone Group...
Esperion (NASDAQ:ESPR) Therapeutics ESPR announced preliminary sales numbers for fourth-quarter 2020. Notably, the company’s expectation for the quarter looks gloomy....
Stocks fought back from another lower open on Friday, but it wasn’t enough to save the whole week as the plunges on Tuesday and Wednesday proved too severe to...
Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy.